What is ArriVent BioPharma, Inc.'s D&A?

ArriVent BioPharma, Inc. (AVBP) reported D&A of -$559K in Q1 2026.

How has ArriVent BioPharma, Inc.'s D&A changed year-over-year?

ArriVent BioPharma, Inc.'s D&A increased by 26.1% year-over-year, from -$756.5K to -$559K.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

ArriVent BioPharma, Inc. AVBP D&A

D&A at other companies

Johnson & JohnsonJNJ

$2B+13.1%

Nuvation BioNUVB

$536K+72.9%

ImmunomeIMNM

$603K-1.3%

Arcus BiosciencesRCUS

$2M-33.3%

Erasca, Inc.ERAS

$723K-12.0%

Bicara TherapeuticsBCAX

$44K+132%

Other financials

Income statement

See full

Operating income-$46.1M+30.9%

Net income-$43.3M+32.7%

EPS (diluted)-$0.96+49.5%

Balance sheet

See full

Cash & equivalents$62.1M+24.5%

Total debt$419.0K+204%

Total equity$324.0M+60.0%

Total assets$349.3M+62.1%

Cash flow

See full

Operating cash flow-$41.9M+38.4%

Valuation

See full

Market cap$1.57B+62.1%

Enterprise value$1.51B+65.4%

Returns & leverage

See full

Return on equity-55.2%+8.0pp

Debt / equity0×0.0×

Current ratio14×-0.4×

Where this comes from

Reported directly by ArriVent BioPharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAmortizationAndAccretionNet.

The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about ArriVent BioPharma, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ArriVent BioPharma, Inc.'s D&A?: ArriVent BioPharma, Inc. (AVBP) reported D&A of -$559K in Q1 2026.
How has ArriVent BioPharma, Inc.'s D&A changed year-over-year?: ArriVent BioPharma, Inc.'s D&A increased by 26.1% year-over-year, from -$756.5K to -$559K.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.